A mitochondria-encoded peptide that activates AMPK and SIRT1 to mimic the metabolic effects of exercise and caloric restriction — supporting insulin sensitivity, metabolic health, and longevity pathways.
| Provider | Type | Price | Review | Link |
|---|---|---|---|---|
| Defy Medical | Telehealth | ~$200/mo | Read review | Get Started → |
| Marek Health | Telehealth | $166/mo | Read review | Get Started → |
| NextGenPeps | Research | $39 / 10mg | — | Visit Site → |
Telehealth = physician-prescribed. Research = for research use only, no prescription required. Learn the difference →
MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded within mitochondrial DNA — making it one of the few known peptides produced by mitochondria rather than the nuclear genome. Discovered in 2015 by researchers at USC, MOTS-C circulates in the bloodstream and acts as a systemic metabolic regulator, particularly in the context of aging and metabolic stress.
MOTS-C activates AMPK (AMP-activated protein kinase) — the master cellular energy sensor — and SIRT1 signaling. These pathways govern glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and insulin sensitivity. In animal studies, MOTS-C administration reversed age-related insulin resistance, improved physical performance, reduced fat accumulation, and extended healthspan. Its effects closely parallel the metabolic adaptations induced by aerobic exercise and caloric restriction.
Users typically report improved energy levels, enhanced workout performance, and better post-meal glucose regulation within 2–4 weeks. Body composition improvements and metabolic marker changes become apparent over 8–12 week cycles. MOTS-C is one of the more cutting-edge longevity peptides, and research in humans is still emerging.
Use code 3LUIZH10 at NextGenPeps for a discount on research-grade MOTS-C.